Incretin-basedTherapyinGuidelines_R2 clean.pdf (270.34 kB)
Download file

Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?

Download (270.34 kB)
journal contribution
posted on 21.04.2020, 10:18 by Melanie J Davies, Cristina Bianchi, Stefano Del Prato

In recent years guidelines for the treatment of type 2 diabetes (T2DM) have evolved substantially. Initially limited to a few glucose lowering agents, early guidelines predicated strict glycemic control as a main goal in the attempt to reduce the risk of long-term diabetic complications. Nowadays, guidelines are not limited to such a goal but include cardiovascular (and renal) protection. This rapid evolution was made possible by the introduction of new glucose lowering agents, which have been extensively tested in randomized clinical studies including large cardiovascular outcome trials (CVOTs). In this review we will specifically consider the use of incretin-based medications in T2DM as recommended in the recent ADA/EASD consensus, and other international guidelines, with special consideration of their glucose-lowering efficacy, their cardiovascular (and renal) benefit, their effect on body weight and risk of hypoglycemia, as well as the economic implications for their use.

Funding

This work was funded by the University of Pisa, Department of Clinical and Experimental Medicine.

History

Citation

Metabolism (2020)

Version

AM (Accepted Manuscript)

Published in

Metabolism

Pagination

154242 - 154242

Publisher

Elsevier BV

issn

0026-0495

Acceptance date

16/04/2020

Copyright date

2020

Available date

18/04/2020

Publisher version

https://www.metabolismjournal.com/article/S0026-0495(20)30106-2/pdf

Language

en

Usage metrics

Categories

Exports